Peter Payne is a seasoned executive with over three decades of experience at the forefront of the pharmaceutical, biotechnology, and contract research organization (CRO) industries. His expertise spans executive leadership, drug development, operational management, and strategic business development, positioning him as a visionary leader dedicated to advancing global healthcare solutions.

Peter most recently served as Vice President, Head of the Digital Research Network at Optum, where he led transformative initiatives from January 2019 to April 2022. In this role, based in Raleigh-Durham, North Carolina, he successfully harnessed innovative technologies to streamline clinical research processes, enhance data-driven insights, and foster collaborations that elevated the organization’s impact on healthcare delivery.

Prior to his tenure at Optum, Peter was the President of Gennaker Bio for over six years, where he provided consulting services to biopharma companiesover. His leadership extended to a period as CEO at Artemis Therapeutics, Inc. in 2017, where he directed corporate strategy, strengthened investor relations and put together a world-class Scientific Advisory Board.

At Chimerix, Inc., Peter played a critical role as Senior Vice President of Business Development & Corporate Strategy, spearheading initiatives that drove corporate growth and re-positioned the company’s therapeutic pipeline. He also conducted due diligence on a large number of potential in-licensing opportunities. Earlier in his career, he led eXcelerate Research as CEO, fostering innovations in clinical research processes. His roles at TcLand Expression as Chief Business Officer and Head of US Operations further showcase his ability to navigate complex cross-border business environments.

Peter’s foundational experience includes a 12-year tenure at Quintiles, where he rose to the position of Vice President of Corporate Development, leading strategic partnerships and advancing clinical operations globally. He also gained international experience as Managing Director of France for Innovex, subsequently acquired by Quintiles. Early in his career he also had roles at ITEM Verum and GlaxoWellcome, where he contributed to groundbreaking clinical research initiatives.

A graduate of The University of Manchester, Peter earned a B.Sc. (Hons) in Pharmacology, providing him with a robust scientific foundation that underpins his business acumen. His commitment to the life sciences field is evident through his extensive skill set, which includes biotechnology, drug discovery, licensing, technology transfer, and strategic planning. With endorsements from industry peers in areas such as clinical development, CRO management, and cross-functional leadership, Peter is widely respected for his ability to drive results in complex and evolving markets.

Known for his visionary approach to business strategy and operational efficiency, Peter has played a pivotal role in fostering innovation and building organizations capable of addressing unmet medical needs. His leadership style emphasizes collaboration, agility, and a relentless focus on delivering value to stakeholders.

• Character: Peter Payne is a highly respected and results-driven leader known for his integrity, dedication, and commitment to advancing healthcare solutions.
• Knowledge: With a deep expertise in pharmaceuticals, biotech, and CRO industries, Peter has a strong foundation in drug development, clinical trials, and corporate strategy.
• Strategic: Peter excels at driving growth and innovation, having led multiple organizations through complex business environments and strategic transformations.
• Communication: He is an effective communicator, fostering collaboration across teams and stakeholders while clearly articulating business goals and vision to achieve impactful results.